Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 6/2016

01-12-2016 | Case Report

Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C

Authors: Ilaria Izzo, Paola Zanotti, Claudia Chirico, Salvatore Casari, Vincenzo Villanacci, Marianna Salemme, Luciano Biasi, Elena Festa, Francesco Castelli

Published in: Infection | Issue 6/2016

Login to get access

Abstract

Since 2014 several direct-acting antivirals (DAAs) have been made available, allowing interferon-free antiviral treatments with high sustained virological response rates. Side effects are, however, a real challenge during treatment. Sarkar et al. recently published a case of colitis following initiation of sofosbuvir and simeprevir for genotype 1 hepatitis C. We report the case of a patient with no prior history of inflammatory bowel disease, who developed significant bloody diarrhea within 3 weeks of sofosbuvir/simeprevir/ribavirin initiation. Colonoscopy and biopsy suggested a drug-induced colitis.
Literature
1.
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333.CrossRefPubMed
2.
Zopf S, Kremer AE, Neurath MF, Siebler J. Advances in hepatitis C therapy: what is the current state—what come’s next? World J Hepatol. 2016;8(3):139–47.CrossRefPubMedPubMedCentral
3.
Sarkar S, Mitchell KA, Lim JK, Oikonomou I, Jakab S. Colitis following initiation of sofosbuvir and simeprevir for genotype 1 hepatitis C. ACG Case Rep J. 2015;3(1):42–4.CrossRefPubMedPubMedCentral
4.
5.
Leung Y, Urbanski SJ, Schindel L, Myers RP. Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Can J Gastroenterol. 2006;20(10):661–3.CrossRefPubMedPubMedCentral
6.
Baik SJ, Kim TH, Yoo K, Moon IH, Cho MS. Ischemic colitis during interferon-ribavirin therapy for chronic hepatitis C: a case report. World J Gastroenterol. 2012;18(31):4233–6.CrossRefPubMedPubMedCentral
7.
Plevy S, Silverberg MS, Lockton S, Stockfisch T, Croner L, Stachelski J, Brown M, Triggs C, Chuang E, Princen F, Singh S. Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn’s disease, and ulcerative colitis patients. Inflamm Bowel Dis. 2013;19(6):1139–48.CrossRefPubMedPubMedCentral
8.
Mc Carthy AJ, Lauwers GY, Sheahan K. Iatrogenic pathology of the intestines. Histopathology. 2015;66(1):15–28.CrossRef
Metadata
Title
Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C
Authors
Ilaria Izzo
Paola Zanotti
Claudia Chirico
Salvatore Casari
Vincenzo Villanacci
Marianna Salemme
Luciano Biasi
Elena Festa
Francesco Castelli
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 6/2016
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-016-0915-x

Other articles of this Issue 6/2016

Infection 6/2016 Go to the issue

Original Paper

Synchronous multifocal necrotizing fasciitis prognostic factors: a retrospective case series study in a single center

Review

Zika virus disease: a current review of the literature

Case Report

Carbapenem-resistant Lactobacillus intra-abdominal infection in a renal transplant recipient with a history of probiotic consumption

Correspondence

Letter to the editor of infection in response to de Francesco et al., a cluster of invasive listeriosis in Brescia, Italy

Images in Infection

A pain in the back: anaerobic vertebral spondylitis of hematogenous origin

Original Paper

CAND-LO 2014–15 study: changing epidemiology of candidemia in Lombardy (Italy)

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits